Journal: Engineering in Life Sciences

Article Title: Identification and natural functions of cyclic lipopeptides from Bacillus amyloliquefaciens An6

doi: 10.1002/elsc.201600050

Figure Lengend Snippet: Antimicrobial activity spectrum of An6 lipopeptides mixture

Article Snippet: An6 lipopeptides mixture was also characterized by an important antifungal activity, especially, against P. ultimum , R. bataticola , and R. solani and lower activity against M. rouxii . table ft1 table-wrap mode="anchored" t5 Table 4 caption a7 Indicator organism Inhibition (mm) Gram‐positive Staphylococcus aureus (ATCC 25923) 18 ± 1.0 b Bacillus cereus (ATCC 11778) 20 ± 1.0 a Enterococcus faecalis (ATCC 29212) 13 ± 2.0 c Micrococcus luteus (ATCC 4698) 15 ± 1.0 c Gram‐negative Pseudomonas aeruginosa (ATCC 27853) 11 ± 1.0 c Klepsiella pneumoniae (ATCC 13883) 8 ± 1.0 d Escherichia coli (ATCC 29212) 17 ± 1.0 b Salmonella typhimurium (ATCC 19430) 11 ± 0.0 c Fungi Rhizoctonia bataticola 17 ± 2.0 b Pythum ultimum 25 ± 2.0 a Rhizoctonia solani 25 ± 1.0 a Fusarum oxysporum 17 ± 1.0 b Mucor rouxii 12 ± 1.0 c Open in a separate window Values are given as mean ± SD from triplicate determinations ( n = 3), a, b, and c in the same column indicated significant differences ( p ˂ 0.05).

Techniques: Activity Assay, Inhibition

Journal:

Article Title: Glycopeptide-Intermediate Staphylococcus aureus : Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals

doi:

Figure Lengend Snippet: S. aureus isolates used in the GISA screen pilot study a

Article Snippet: Test plates were incubated with no more than two in a stack in ambient air at 35°C and examined for growth after 24 and 48 h. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Isolate Vancomycin MIC or range (μg/ml) Interpretation GISA isolates S. aureus Japan strain Mu3 2 S S. aureus Florida strain 800 2 S S. aureus Japan strain N20 4 S S. aureus Michigan strain 966 4 S S. aureus Florida strain 803 4 S S. aureus Japan strain Mu50 8 I S. aureus Japan strain Mu3-8R 8 I S. aureus Michigan strain 963sm 8 I S. aureus New Jersey strain 992 8 I Quality-control isolates S. aureus ATCC 29213 0.5–2 S S. aureus ATCC 25923 2 S E. faecalis ATCC 29212 1–4 S E. faecalis ATCC 51299 16–32 R Open in a separate window a Abbreviations in the interpretation column reflect NCCLS interpretive categories (S, susceptible; I, intermediate; and R, resistant).

Techniques:

Journal:

Article Title: Glycopeptide-Intermediate Staphylococcus aureus : Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals

doi:

Figure Lengend Snippet: Quality-control results of MHA-vancomycin agar pilot screen testing after 24 h

Article Snippet: Test plates were incubated with no more than two in a stack in ambient air at 35°C and examined for growth after 24 and 48 h. table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Isolate Vancomycin MIC or range (μg/ml) Interpretation GISA isolates S. aureus Japan strain Mu3 2 S S. aureus Florida strain 800 2 S S. aureus Japan strain N20 4 S S. aureus Michigan strain 966 4 S S. aureus Florida strain 803 4 S S. aureus Japan strain Mu50 8 I S. aureus Japan strain Mu3-8R 8 I S. aureus Michigan strain 963sm 8 I S. aureus New Jersey strain 992 8 I Quality-control isolates S. aureus ATCC 29213 0.5–2 S S. aureus ATCC 25923 2 S E. faecalis ATCC 29212 1–4 S E. faecalis ATCC 51299 16–32 R Open in a separate window a Abbreviations in the interpretation column reflect NCCLS interpretive categories (S, susceptible; I, intermediate; and R, resistant).

Techniques:

Journal: Journal of Clinical Microbiology

Article Title: Evaluation of Luminex xTAG Fungal Analyte-Specific Reagents for Rapid Identification of Clinically Relevant Fungi ^▿

doi: 10.1128/JCM.01135-11

Figure Lengend Snippet: Fungal and bacterial strains used in this study

Article Snippet: A slide culture on potato dextrose agar was also performed when necessary. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 Organism Source No. of strains Candida albicans ATCC 18804 1 Clinical isolates 9 Candida glabrata Clinical isolates 6 Candida parapsilosis ATCC 22019 1 Clinical isolates 5 Candida tropicalis ATCC 750 1 Clinical isolates 5 Candida lusitaniae Proficiency organism 1 Clinical isolates 6 Candida krusei ATCC 6258 1 Clinical isolates 4 Candida guilliermondii ATCC 6260 1 Clinical isolates 2 Aspergillus fumigatus Clinical isolates 8 Aspergillus flavus Clinical isolates 5 Aspergillus terreus Clinical isolates 4 Aspergillus niger ATCC 16404 1 Clinical isolates 7 Fusarium species Clinical isolates 3 Scedosporium apiospermum Clinical isolates 7 Scedosporium prolificans Clinical isolates 2 Cunninghamella bertholletiae Clinical isolates 2 Mucor species Clinical isolates 6 Rhizopus species Clinical isolates 5 Rhizopus microsporus Clinical isolate 1 Staphylococcus aureus ATCC 29213 1 ATCC 43300 1 Staphylococcus epidermidis ATCC 12228 1 Streptococcus pyogenes ATCC 19615 1 Streptococcus pneumoniae ATCC 49136 1 Streptococcus bovis ATCC 49147 1 Enterococcus faecalis ATCC 29212 1 Escherichia coli ATCC 25922 1 ATCC 35218 1 Klebsiella pneumoniae ATCC 35657 1 Proteus mirabilis ATCC 35659 1 Proteus vulgaris ATCC 49132 1 Enterobacter cloacae ATCC 13047 1 Haemophilus influenzae ATCC 9006 1 Micrococcus luteus ATCC 4698 1 Moraxella catarrhalis ATCC 8176 1 Open in a separate window Fungal and bacterial strains used in this study Clinical specimens.

Techniques: